Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pre-Eclampsia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H1 2015', provides an overview of the Pre-Eclampsia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pre-Eclampsia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pre-Eclampsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pre-Eclampsia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pre-Eclampsia Overview 6 Therapeutics Development 7 Pipeline Products for Pre-Eclampsia - Overview 7 Pipeline Products for Pre-Eclampsia - Comparative Analysis 8 Pre-Eclampsia - Therapeutics under Development by Companies 9 Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes 10 Pre-Eclampsia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Pre-Eclampsia - Products under Development by Companies 14 Pre-Eclampsia - Products under Investigation by Universities/Institutes 15 Pre-Eclampsia - Companies Involved in Therapeutics Development 16 A1M Pharma AB 16 Alnylam Pharmaceuticals, Inc. 17 Glenveigh Medical, LLC 18 Pluristem Therapeutics Inc. 19 rEVO Biologics 20 VG Life Sciences, Inc. 21 Pre-Eclampsia - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 ALN-AGT - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Alpha-1-Microglobulin - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 antithrombin alfa (recombinant) - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 digoxin immune fab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Stem Cell Therapy for Pre-Eclampsia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VG-1177 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Pre-Eclampsia - Recent Pipeline Updates 40 Pre-Eclampsia - Dormant Projects 42 Pre-Eclampsia - Product Development Milestones 43 Featured News & Press Releases 43 Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia 43 Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 44 Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1) 44 Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia 45 Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia 46 Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia 46 Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Preeclampsia 47 Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables Number of Products under Development for Pre-Eclampsia, H1 2015 7 Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Pre-Eclampsia - Pipeline by A1M Pharma AB, H1 2015 16 Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 17 Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H1 2015 18 Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H1 2015 19 Pre-Eclampsia - Pipeline by rEVO Biologics, H1 2015 20 Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H1 2015 40 Pre-Eclampsia - Dormant Projects, H1 2015 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
